Glow Lifetech（9DO）株式概要バイオテクノロジー企業であるグロー・ライフテック社は、栄養補助食品とカンナビノイドをベースとした製品の製造に注力している。 詳細9DO ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6報酬過去5年間の収益は年間41.2%増加しました。 リスク分析German市場と比較して、過去 3 か月間の株価の変動が非常に大きい意味のある時価総額がありません ( €6M )意味のある収益がありません ( CA$2M )すべてのリスクチェックを見る9DO Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€0.01890.8% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-11m46m2016201920222025202620282031Revenue CA$45.6mEarnings CA$6.7mAdvancedSet Fair ValueView all narrativesGlow Lifetech Corp. 競合他社TFF PharmaceuticalsSymbol: MUN:0K30Market cap: €9.7mBiofronteraSymbol: XTRA:B8FKMarket cap: €14.7mCantourage GroupSymbol: XTRA:HIGHMarket cap: €75.6mOncoZengeSymbol: OM:ONCOZMarket cap: SEK 102.3m価格と性能株価の高値、安値、推移の概要Glow Lifetech過去の株価現在の株価CA$0.01852週高値CA$0.04952週安値CA$0.004ベータ1.391ヶ月の変化-31.48%3ヶ月変化-19.57%1年変化-33.93%3年間の変化-68.64%5年間の変化-92.60%IPOからの変化-95.09%最新ニュースお知らせ • Jan 07Glow Lifetech Corp. Expands into Medical Cannabis Channel with National Launch on MendoGlow Lifetech Corp. announced the launch of its MOD™? and .decimal™? product portfolio on the Mendo Medical Cannabis platform ("Mendo"), representing Glow's first formal entry into the Canadian medical cannabis channel and extending access to its products for registered medical patients nationwide. This launch represents an important milestone in Glow's commercial strategy, making its full portfolio (14 SKUs) of next-generation cannabis products available to medical patients across Canada, including veterans, who value greater consistency, dose-control, and personalization. Mendo Medical Cannabis is one of Canada's leading medical cannabis providers, serving registered patients across Canada, with a long-standing focus on veterans through dedicated support programs. Based in Quebec, Mendo operates a national online sales platform, providing both civilians and veterans with easy, secure access to high-quality cannabis products from Canada's top licensed producers. The addition of the medical channel further diversifies Glow's distribution mix heading into 2026 and reinforces the scalability of its business model. Alongside its growing presence with major provincial retailers, this expansion positions the Company to serve a broader customer base while maintaining focus on operational efficiency and long-term value creation.お知らせ • Jun 23Glow Lifetech Corp., Annual General Meeting, Aug 28, 2025Glow Lifetech Corp., Annual General Meeting, Aug 28, 2025.お知らせ • Jun 03Glow Lifetech Corp. Announces the Resignation of James Van Staveren from the Board of DirectorsGlow Lifetech Corp. announced that Mr. James Van Staveren has resigned from the Board of Directors of the Company, effective May 31, 2025.お知らせ • Jan 29Glow Lifetech Corp. Announces Executive and Board ChangesGlow LifeTech Corp. announced the appointment of David Ct as a new independent director to the Board of Directors (the "Board"), effective January 24, 2025. Mr. Ct is a seasoned leader in the cannabis retail industry, with extensive experience scaling retail operations and driving growth. David currently serves as Chief Executive Officer of J. Supply Holdings Inc., which owns the cannabis retail banners Northern Helm and J. Supply Co. Prior to this, David was Director of Retail Strategy at Canopy Growth Corporation, where he developed the model for franchising retail cannabis stores across Canada. These endeavours are built on a career in retail, leveraging learnings from the quick-service restaurant, consulting, and CPG industries to the cannabis space, having spent time at RBI, Accenture, and SC Johnson. David earned his MBA and HBA from the Ivey School of Business. The Company also wishes to announced that James Van Staveren has resigned from his position as a member of Glow's Audit Committee and as Corporate Secretary, effective January 24, 2025. Mr. Van Staveren will remain as a director on the Board. Glow would like to sincerely thank Mr. Van Staveren for his valuable services to the Company in his capacity as a member of Glow's Audit Committee and as Corporate Secretary. Effective January 24, 2025, Mr. Ct has been appointed to Glow's Audit Committee and Josh Bald, the Company's Chief Financial Officer, has been appointed as Corporate Secretary.お知らせ • Nov 06Glow Lifetech Corp. announced that it expects to receive CAD 0.9 million in fundingGlow Lifetech Corp. announced a non-brokered private placement that it will issue up to 18,000,000 units at an issue price of CAD 0.05 per unit for the gross proceeds of up to CAD 900,000 on November 5, 2024. Each Unit issued under the Offering will consist of one Share and one half of one common share purchase warrant. Each full Warrant will be exercisable to acquire one Share for a period of eighteen months following the closing of the Offering, at an exercise price of CAD 0.07 per Warrant Share. All securities issued in connection with the Offering will be subject to a four month and one day hold as required under applicable securities lawsNew Risk • Sep 30New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 113% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-CA$214k). Shareholders have been substantially diluted in the past year (113% increase in shares outstanding). Revenue is less than US$1m (CA$345k revenue, or US$255k). Market cap is less than US$10m (€4.42m market cap, or US$4.94m).最新情報をもっと見るRecent updatesお知らせ • Jan 07Glow Lifetech Corp. Expands into Medical Cannabis Channel with National Launch on MendoGlow Lifetech Corp. announced the launch of its MOD™? and .decimal™? product portfolio on the Mendo Medical Cannabis platform ("Mendo"), representing Glow's first formal entry into the Canadian medical cannabis channel and extending access to its products for registered medical patients nationwide. This launch represents an important milestone in Glow's commercial strategy, making its full portfolio (14 SKUs) of next-generation cannabis products available to medical patients across Canada, including veterans, who value greater consistency, dose-control, and personalization. Mendo Medical Cannabis is one of Canada's leading medical cannabis providers, serving registered patients across Canada, with a long-standing focus on veterans through dedicated support programs. Based in Quebec, Mendo operates a national online sales platform, providing both civilians and veterans with easy, secure access to high-quality cannabis products from Canada's top licensed producers. The addition of the medical channel further diversifies Glow's distribution mix heading into 2026 and reinforces the scalability of its business model. Alongside its growing presence with major provincial retailers, this expansion positions the Company to serve a broader customer base while maintaining focus on operational efficiency and long-term value creation.お知らせ • Jun 23Glow Lifetech Corp., Annual General Meeting, Aug 28, 2025Glow Lifetech Corp., Annual General Meeting, Aug 28, 2025.お知らせ • Jun 03Glow Lifetech Corp. Announces the Resignation of James Van Staveren from the Board of DirectorsGlow Lifetech Corp. announced that Mr. James Van Staveren has resigned from the Board of Directors of the Company, effective May 31, 2025.お知らせ • Jan 29Glow Lifetech Corp. Announces Executive and Board ChangesGlow LifeTech Corp. announced the appointment of David Ct as a new independent director to the Board of Directors (the "Board"), effective January 24, 2025. Mr. Ct is a seasoned leader in the cannabis retail industry, with extensive experience scaling retail operations and driving growth. David currently serves as Chief Executive Officer of J. Supply Holdings Inc., which owns the cannabis retail banners Northern Helm and J. Supply Co. Prior to this, David was Director of Retail Strategy at Canopy Growth Corporation, where he developed the model for franchising retail cannabis stores across Canada. These endeavours are built on a career in retail, leveraging learnings from the quick-service restaurant, consulting, and CPG industries to the cannabis space, having spent time at RBI, Accenture, and SC Johnson. David earned his MBA and HBA from the Ivey School of Business. The Company also wishes to announced that James Van Staveren has resigned from his position as a member of Glow's Audit Committee and as Corporate Secretary, effective January 24, 2025. Mr. Van Staveren will remain as a director on the Board. Glow would like to sincerely thank Mr. Van Staveren for his valuable services to the Company in his capacity as a member of Glow's Audit Committee and as Corporate Secretary. Effective January 24, 2025, Mr. Ct has been appointed to Glow's Audit Committee and Josh Bald, the Company's Chief Financial Officer, has been appointed as Corporate Secretary.お知らせ • Nov 06Glow Lifetech Corp. announced that it expects to receive CAD 0.9 million in fundingGlow Lifetech Corp. announced a non-brokered private placement that it will issue up to 18,000,000 units at an issue price of CAD 0.05 per unit for the gross proceeds of up to CAD 900,000 on November 5, 2024. Each Unit issued under the Offering will consist of one Share and one half of one common share purchase warrant. Each full Warrant will be exercisable to acquire one Share for a period of eighteen months following the closing of the Offering, at an exercise price of CAD 0.07 per Warrant Share. All securities issued in connection with the Offering will be subject to a four month and one day hold as required under applicable securities lawsNew Risk • Sep 30New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 113% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-CA$214k). Shareholders have been substantially diluted in the past year (113% increase in shares outstanding). Revenue is less than US$1m (CA$345k revenue, or US$255k). Market cap is less than US$10m (€4.42m market cap, or US$4.94m).お知らせ • Sep 25Glow Lifetech Corp. announced that it has received CAD 1.2 million in fundingOn September 24,2024 Glow Lifetech Corp. closed the transaction. In connection with the Offering, the Company paid certain eligible persons: (i) cash commissions in the aggregate of CAD 2,400; and (ii) issued an aggregate of 80,000 finder warrants to such Finders. Each Finder Warrant is exercisable at a price of CAD 0.05 per Common Share until the date that is eighteen (18) months from the date of issuance. The Offering was approved by the members of the board of directors of the Company who are independent for the purposes of the Offering.お知らせ • Aug 14Glow Lifetech Corp. announced that it expects to receive CAD 1.2 million in fundingGlow Lifetech Corp announced a non-brokered private placement financing of up to 40,000,000 units at a price of CAD 0.03 per Unit for gross proceeds CAD 1,200,000 on August 14, 2024. Each Unit shall be comprised of one common share in the capital of the Company and one Common Share purchase warrant. Each Warrant entitles the holder thereof to acquire one Common Share at a price of CAD 0.05 per Common Share for a period of eighteen months from the date of issuance. Closing of the Offering is subject to receipt of all necessary corporate and regulatory approvals. All securities issued in connection with the Offering will be subject to a hold period of four months plus a day from the date of issuance and the resale rules of applicable securities legislation.Board Change • Aug 07Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 1 independent director (2 non-independent directors). CEO & Director Rob Carducci is the most experienced director on the board, commencing their role in 2021. Independent Director Daniel Proska was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Apr 17Glow Lifetech Corp. announced that it expects to receive CAD 0.75 million in fundingGlow Lifetech Corp. announced a non-brokered private placement financing of 25,000,000 units at issue price CAD 0.03 per unit for gross proceeds of CAD 750,000 on April 16, 2024. Each unit shall comprise one common share in the capital of the company and one common share purchase warrant. Each warrant entitles the holder thereof to acquire one common share at a price of five cents per common share for a period of 18 months from the date of issuance. Closing of the offering is subject to receipt of all necessary corporate and regulatory approvals, including the approval of Canadian Securities Exchange. All securities issued in connection with the offering will be subject to a hold period of four months plus a day from the date of issuance and the resale rules of applicable securities legislation.New Risk • Feb 18New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (66% average weekly change). Revenue is less than US$1m (CA$19k revenue, or US$14k). Market cap is less than US$10m (€1.27m market cap, or US$1.36m). Minor Risk Shareholders have been diluted in the past year (7.4% increase in shares outstanding).Board Change • Jan 16High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. Chief Commercial Officer & Director Rob Carducci is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Dec 17Glow Lifetech Corp. announced that it expects to receive CAD 0.25 million in fundingGlow Lifetech Corp. announced a non-brokered private placement of up to 5,000,000 units in the capital of the company at a price of CAD 0.05 per unit for the gross proceeds of up to CAD 250,000 on December 15, 2023. Each unit shall be comprised of one common share in the capital of the company and one common share purchase warrant. Each warrant entitles the holder thereof to acquire one common share at a price of CAD 0.07 per common share for a period of 18 months from the date of issuance. The transaction is subject to receipt of all necessary corporate and regulatory approvals. All securities issued in connection with the Offering will be subject to a hold period of four months plus a day from the date of issuance and the resale rules of applicable securities legislation.Board Change • Nov 02High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. Chief Commercial Officer & Director Rob Carducci is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Sep 08Glow Lifetech Corp. Appoints Daniel Proska to Its Board of DirectorsGlow LifeTech Corp. announce the appointment of Daniel Proska as a new independent director to the Board of Directors, effective, September 6, 2023. With over 15 years of experience in senior sales and revenue growth roles across diverse sectors ranging from medical devices and robotics to software and cybersecurity Mr. Proska has demonstrated a unique capacity for driving business expansion. Notably, his contributions were pivotal in Venus Concepts' growth from $5 million to over $100 million in revenue, and supporting its growth to a NASDAQ listing. Proska's extensive experience in both commercial strategy and operating within regulated environments makes him an invaluable asset to Glow LifeTech. His familiarity with the regulatory complexities in industries such as medical devices and cybersecurity will complement his commercial and strategic acumen, further empowering the Company as it introduces its technology and products to Canada's tightly-regulated emerging cannabis market. Currently, Mr. Proska serves as the Chief Commercial Officer at Scryb Inc., an A.I. Platform that enables businesses across industries to create, enhance, and power disruptive solutions. Among the companies that have benefited from Scryb's capabilities is Cybeats Technologies Corp., a cybersecurity firm where Mr. Proska has contributed to the acquisition of Fortune 500 clients, affirming his capabilities to drive revenue growth and business outcomes. Chris Irwin will step down from his duties as a director of Glow, effective September 6, 2023.お知らせ • Jul 07Glow Expands Technology Portfolio and Proprietary Product Format Capabilities; Develops New Water-Soluble Cannabis Powder TechnologyGlow LifeTech Corp. announce that it has developed a proprietary, water-soluble cannabis powder technology ("New Powder Technology''), which expands the Company's technology portfolio to both liquid and powder cannabinoid ingredients and unlocks a new range of product format capabilities. To protect the New Powder Technology, the Company has submitted provisional patent applications with the United States Patent and Trademark Office. The Company's New Powder Technology creates dry powder cannabinoids that are water-soluble and designed for improved absorption, great taste and a more consistent and predictable cannabis experience. Building on the Company's existing nature-based liquid MyCell® Technology, the New Powder Technology is uniquely made with only natural, plant-based ingredients, and cannabis extracts including THC, CBD, CBN and CBG distillates and isolates. The new powder ingredients expands Glow's growing portfolio of high-performance ingredients, and allows the Company to support a variety of new product formats including capsules, drink mixes, gummies, infused-foods, and more. The Company submitted provisional patent applications to the United States Patent and Trademark Office (USPTO) as part of its ongoing IP strategy for the powder technology. The filings allow Glow to ascribe the phrase "patent pending" to any commercial products, methods, or services contemplated by the subject matter claimed. The patent applications reflect Glow's strategy of strengthening its IP portfolio relating to cannabis and nutraceutical ingredient technologies. MyCell® Technology is Glow's proprietary delivery system that optimizes the absorption, bioavailability and effectiveness of natural active compounds including vitamins, cannabinoids and botanicals, using only 100% natural, food-grade components. It transforms poorly absorbed natural compounds into water-compatible concentrates that have fast-acting onset, high-absorption, precision dosing and a clean taste profile. With its portfolio of ingredients, Glow is powering a new era of more efficient, fast-acting, and great tasting functional foods, beverages, supplements, and personal care products.お知らせ • Dec 09Glow Lifetech Corp., Annual General Meeting, Feb 22, 2023Glow Lifetech Corp., Annual General Meeting, Feb 22, 2023.Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Member of Technical Advisory Board Murray Berall was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Member of Technical Advisory Board Murray Berall was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Sep 17No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.株主還元9DODE PharmaceuticalsDE 市場7D-51.3%6.1%3.2%1Y-33.9%27.3%2.5%株主還元を見る業界別リターン: 9DO過去 1 年間で27.3 % の収益を上げたGerman Pharmaceuticals業界を下回りました。リターン対市場: 9DOは、過去 1 年間で2.5 % のリターンを上げたGerman市場を下回りました。価格変動Is 9DO's price volatile compared to industry and market?9DO volatility9DO Average Weekly Movement269.6%Pharmaceuticals Industry Average Movement6.3%Market Average Movement6.1%10% most volatile stocks in DE Market13.6%10% least volatile stocks in DE Market2.7%安定した株価: 9DOの株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 9DOの 週次ボラティリティ は、過去 1 年間で148%から270%に増加しました。会社概要設立従業員CEO（最高経営責任者ウェブサイト1988n/aRob Carducciglowlifetech.comバイオテクノロジー企業であるグローライフテック社は、栄養補助食品とカンナビノイドをベースとした製品の製造に注力している。同社は、植物ベースのマイセル・テクノロジー・デリバリー・システム、水溶性成分、カスタマイズ・ブレンド、粉末ベースのカプセル、および市販可能な製品の商品化に取り組んでいる。大麻・麻由来成分、クルクミン、ビタミンK、鉄のミセル化技術の北米における製造・販売・流通権を独占的に保有。特定のビタミン、栄養補助食品、大麻エキスを二次加工し、脂溶性物質を即座に体内に吸収させるミセル化素材を製造し、バイオアベイラビリティ（生物学的利用能）と水適合性をほぼ100％に近づける事業を行っている。同社はMODと decimalブランドで製品を提供している。グローライフテック社は1988年に設立され、カナダのトロントに本社を置いている。もっと見るGlow Lifetech Corp. 基礎のまとめGlow Lifetech の収益と売上を時価総額と比較するとどうか。9DO 基礎統計学時価総額€6.00m収益（TTM）-€385.35k売上高(TTM)€1.28m5.2xP/Sレシオ-17.1xPER（株価収益率9DO は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計9DO 損益計算書（TTM）収益CA$2.05m売上原価CA$1.01m売上総利益CA$1.05mその他の費用CA$1.66m収益-CA$617.86k直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.0032グロス・マージン50.94%純利益率-30.09%有利子負債／自己資本比率0%9DO の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 19:10終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Glow Lifetech Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jan 07Glow Lifetech Corp. Expands into Medical Cannabis Channel with National Launch on MendoGlow Lifetech Corp. announced the launch of its MOD™? and .decimal™? product portfolio on the Mendo Medical Cannabis platform ("Mendo"), representing Glow's first formal entry into the Canadian medical cannabis channel and extending access to its products for registered medical patients nationwide. This launch represents an important milestone in Glow's commercial strategy, making its full portfolio (14 SKUs) of next-generation cannabis products available to medical patients across Canada, including veterans, who value greater consistency, dose-control, and personalization. Mendo Medical Cannabis is one of Canada's leading medical cannabis providers, serving registered patients across Canada, with a long-standing focus on veterans through dedicated support programs. Based in Quebec, Mendo operates a national online sales platform, providing both civilians and veterans with easy, secure access to high-quality cannabis products from Canada's top licensed producers. The addition of the medical channel further diversifies Glow's distribution mix heading into 2026 and reinforces the scalability of its business model. Alongside its growing presence with major provincial retailers, this expansion positions the Company to serve a broader customer base while maintaining focus on operational efficiency and long-term value creation.
お知らせ • Jun 23Glow Lifetech Corp., Annual General Meeting, Aug 28, 2025Glow Lifetech Corp., Annual General Meeting, Aug 28, 2025.
お知らせ • Jun 03Glow Lifetech Corp. Announces the Resignation of James Van Staveren from the Board of DirectorsGlow Lifetech Corp. announced that Mr. James Van Staveren has resigned from the Board of Directors of the Company, effective May 31, 2025.
お知らせ • Jan 29Glow Lifetech Corp. Announces Executive and Board ChangesGlow LifeTech Corp. announced the appointment of David Ct as a new independent director to the Board of Directors (the "Board"), effective January 24, 2025. Mr. Ct is a seasoned leader in the cannabis retail industry, with extensive experience scaling retail operations and driving growth. David currently serves as Chief Executive Officer of J. Supply Holdings Inc., which owns the cannabis retail banners Northern Helm and J. Supply Co. Prior to this, David was Director of Retail Strategy at Canopy Growth Corporation, where he developed the model for franchising retail cannabis stores across Canada. These endeavours are built on a career in retail, leveraging learnings from the quick-service restaurant, consulting, and CPG industries to the cannabis space, having spent time at RBI, Accenture, and SC Johnson. David earned his MBA and HBA from the Ivey School of Business. The Company also wishes to announced that James Van Staveren has resigned from his position as a member of Glow's Audit Committee and as Corporate Secretary, effective January 24, 2025. Mr. Van Staveren will remain as a director on the Board. Glow would like to sincerely thank Mr. Van Staveren for his valuable services to the Company in his capacity as a member of Glow's Audit Committee and as Corporate Secretary. Effective January 24, 2025, Mr. Ct has been appointed to Glow's Audit Committee and Josh Bald, the Company's Chief Financial Officer, has been appointed as Corporate Secretary.
お知らせ • Nov 06Glow Lifetech Corp. announced that it expects to receive CAD 0.9 million in fundingGlow Lifetech Corp. announced a non-brokered private placement that it will issue up to 18,000,000 units at an issue price of CAD 0.05 per unit for the gross proceeds of up to CAD 900,000 on November 5, 2024. Each Unit issued under the Offering will consist of one Share and one half of one common share purchase warrant. Each full Warrant will be exercisable to acquire one Share for a period of eighteen months following the closing of the Offering, at an exercise price of CAD 0.07 per Warrant Share. All securities issued in connection with the Offering will be subject to a four month and one day hold as required under applicable securities laws
New Risk • Sep 30New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 113% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-CA$214k). Shareholders have been substantially diluted in the past year (113% increase in shares outstanding). Revenue is less than US$1m (CA$345k revenue, or US$255k). Market cap is less than US$10m (€4.42m market cap, or US$4.94m).
お知らせ • Jan 07Glow Lifetech Corp. Expands into Medical Cannabis Channel with National Launch on MendoGlow Lifetech Corp. announced the launch of its MOD™? and .decimal™? product portfolio on the Mendo Medical Cannabis platform ("Mendo"), representing Glow's first formal entry into the Canadian medical cannabis channel and extending access to its products for registered medical patients nationwide. This launch represents an important milestone in Glow's commercial strategy, making its full portfolio (14 SKUs) of next-generation cannabis products available to medical patients across Canada, including veterans, who value greater consistency, dose-control, and personalization. Mendo Medical Cannabis is one of Canada's leading medical cannabis providers, serving registered patients across Canada, with a long-standing focus on veterans through dedicated support programs. Based in Quebec, Mendo operates a national online sales platform, providing both civilians and veterans with easy, secure access to high-quality cannabis products from Canada's top licensed producers. The addition of the medical channel further diversifies Glow's distribution mix heading into 2026 and reinforces the scalability of its business model. Alongside its growing presence with major provincial retailers, this expansion positions the Company to serve a broader customer base while maintaining focus on operational efficiency and long-term value creation.
お知らせ • Jun 23Glow Lifetech Corp., Annual General Meeting, Aug 28, 2025Glow Lifetech Corp., Annual General Meeting, Aug 28, 2025.
お知らせ • Jun 03Glow Lifetech Corp. Announces the Resignation of James Van Staveren from the Board of DirectorsGlow Lifetech Corp. announced that Mr. James Van Staveren has resigned from the Board of Directors of the Company, effective May 31, 2025.
お知らせ • Jan 29Glow Lifetech Corp. Announces Executive and Board ChangesGlow LifeTech Corp. announced the appointment of David Ct as a new independent director to the Board of Directors (the "Board"), effective January 24, 2025. Mr. Ct is a seasoned leader in the cannabis retail industry, with extensive experience scaling retail operations and driving growth. David currently serves as Chief Executive Officer of J. Supply Holdings Inc., which owns the cannabis retail banners Northern Helm and J. Supply Co. Prior to this, David was Director of Retail Strategy at Canopy Growth Corporation, where he developed the model for franchising retail cannabis stores across Canada. These endeavours are built on a career in retail, leveraging learnings from the quick-service restaurant, consulting, and CPG industries to the cannabis space, having spent time at RBI, Accenture, and SC Johnson. David earned his MBA and HBA from the Ivey School of Business. The Company also wishes to announced that James Van Staveren has resigned from his position as a member of Glow's Audit Committee and as Corporate Secretary, effective January 24, 2025. Mr. Van Staveren will remain as a director on the Board. Glow would like to sincerely thank Mr. Van Staveren for his valuable services to the Company in his capacity as a member of Glow's Audit Committee and as Corporate Secretary. Effective January 24, 2025, Mr. Ct has been appointed to Glow's Audit Committee and Josh Bald, the Company's Chief Financial Officer, has been appointed as Corporate Secretary.
お知らせ • Nov 06Glow Lifetech Corp. announced that it expects to receive CAD 0.9 million in fundingGlow Lifetech Corp. announced a non-brokered private placement that it will issue up to 18,000,000 units at an issue price of CAD 0.05 per unit for the gross proceeds of up to CAD 900,000 on November 5, 2024. Each Unit issued under the Offering will consist of one Share and one half of one common share purchase warrant. Each full Warrant will be exercisable to acquire one Share for a period of eighteen months following the closing of the Offering, at an exercise price of CAD 0.07 per Warrant Share. All securities issued in connection with the Offering will be subject to a four month and one day hold as required under applicable securities laws
New Risk • Sep 30New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 113% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-CA$214k). Shareholders have been substantially diluted in the past year (113% increase in shares outstanding). Revenue is less than US$1m (CA$345k revenue, or US$255k). Market cap is less than US$10m (€4.42m market cap, or US$4.94m).
お知らせ • Sep 25Glow Lifetech Corp. announced that it has received CAD 1.2 million in fundingOn September 24,2024 Glow Lifetech Corp. closed the transaction. In connection with the Offering, the Company paid certain eligible persons: (i) cash commissions in the aggregate of CAD 2,400; and (ii) issued an aggregate of 80,000 finder warrants to such Finders. Each Finder Warrant is exercisable at a price of CAD 0.05 per Common Share until the date that is eighteen (18) months from the date of issuance. The Offering was approved by the members of the board of directors of the Company who are independent for the purposes of the Offering.
お知らせ • Aug 14Glow Lifetech Corp. announced that it expects to receive CAD 1.2 million in fundingGlow Lifetech Corp announced a non-brokered private placement financing of up to 40,000,000 units at a price of CAD 0.03 per Unit for gross proceeds CAD 1,200,000 on August 14, 2024. Each Unit shall be comprised of one common share in the capital of the Company and one Common Share purchase warrant. Each Warrant entitles the holder thereof to acquire one Common Share at a price of CAD 0.05 per Common Share for a period of eighteen months from the date of issuance. Closing of the Offering is subject to receipt of all necessary corporate and regulatory approvals. All securities issued in connection with the Offering will be subject to a hold period of four months plus a day from the date of issuance and the resale rules of applicable securities legislation.
Board Change • Aug 07Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 1 independent director (2 non-independent directors). CEO & Director Rob Carducci is the most experienced director on the board, commencing their role in 2021. Independent Director Daniel Proska was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Apr 17Glow Lifetech Corp. announced that it expects to receive CAD 0.75 million in fundingGlow Lifetech Corp. announced a non-brokered private placement financing of 25,000,000 units at issue price CAD 0.03 per unit for gross proceeds of CAD 750,000 on April 16, 2024. Each unit shall comprise one common share in the capital of the company and one common share purchase warrant. Each warrant entitles the holder thereof to acquire one common share at a price of five cents per common share for a period of 18 months from the date of issuance. Closing of the offering is subject to receipt of all necessary corporate and regulatory approvals, including the approval of Canadian Securities Exchange. All securities issued in connection with the offering will be subject to a hold period of four months plus a day from the date of issuance and the resale rules of applicable securities legislation.
New Risk • Feb 18New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (66% average weekly change). Revenue is less than US$1m (CA$19k revenue, or US$14k). Market cap is less than US$10m (€1.27m market cap, or US$1.36m). Minor Risk Shareholders have been diluted in the past year (7.4% increase in shares outstanding).
Board Change • Jan 16High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. Chief Commercial Officer & Director Rob Carducci is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Dec 17Glow Lifetech Corp. announced that it expects to receive CAD 0.25 million in fundingGlow Lifetech Corp. announced a non-brokered private placement of up to 5,000,000 units in the capital of the company at a price of CAD 0.05 per unit for the gross proceeds of up to CAD 250,000 on December 15, 2023. Each unit shall be comprised of one common share in the capital of the company and one common share purchase warrant. Each warrant entitles the holder thereof to acquire one common share at a price of CAD 0.07 per common share for a period of 18 months from the date of issuance. The transaction is subject to receipt of all necessary corporate and regulatory approvals. All securities issued in connection with the Offering will be subject to a hold period of four months plus a day from the date of issuance and the resale rules of applicable securities legislation.
Board Change • Nov 02High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. Chief Commercial Officer & Director Rob Carducci is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Sep 08Glow Lifetech Corp. Appoints Daniel Proska to Its Board of DirectorsGlow LifeTech Corp. announce the appointment of Daniel Proska as a new independent director to the Board of Directors, effective, September 6, 2023. With over 15 years of experience in senior sales and revenue growth roles across diverse sectors ranging from medical devices and robotics to software and cybersecurity Mr. Proska has demonstrated a unique capacity for driving business expansion. Notably, his contributions were pivotal in Venus Concepts' growth from $5 million to over $100 million in revenue, and supporting its growth to a NASDAQ listing. Proska's extensive experience in both commercial strategy and operating within regulated environments makes him an invaluable asset to Glow LifeTech. His familiarity with the regulatory complexities in industries such as medical devices and cybersecurity will complement his commercial and strategic acumen, further empowering the Company as it introduces its technology and products to Canada's tightly-regulated emerging cannabis market. Currently, Mr. Proska serves as the Chief Commercial Officer at Scryb Inc., an A.I. Platform that enables businesses across industries to create, enhance, and power disruptive solutions. Among the companies that have benefited from Scryb's capabilities is Cybeats Technologies Corp., a cybersecurity firm where Mr. Proska has contributed to the acquisition of Fortune 500 clients, affirming his capabilities to drive revenue growth and business outcomes. Chris Irwin will step down from his duties as a director of Glow, effective September 6, 2023.
お知らせ • Jul 07Glow Expands Technology Portfolio and Proprietary Product Format Capabilities; Develops New Water-Soluble Cannabis Powder TechnologyGlow LifeTech Corp. announce that it has developed a proprietary, water-soluble cannabis powder technology ("New Powder Technology''), which expands the Company's technology portfolio to both liquid and powder cannabinoid ingredients and unlocks a new range of product format capabilities. To protect the New Powder Technology, the Company has submitted provisional patent applications with the United States Patent and Trademark Office. The Company's New Powder Technology creates dry powder cannabinoids that are water-soluble and designed for improved absorption, great taste and a more consistent and predictable cannabis experience. Building on the Company's existing nature-based liquid MyCell® Technology, the New Powder Technology is uniquely made with only natural, plant-based ingredients, and cannabis extracts including THC, CBD, CBN and CBG distillates and isolates. The new powder ingredients expands Glow's growing portfolio of high-performance ingredients, and allows the Company to support a variety of new product formats including capsules, drink mixes, gummies, infused-foods, and more. The Company submitted provisional patent applications to the United States Patent and Trademark Office (USPTO) as part of its ongoing IP strategy for the powder technology. The filings allow Glow to ascribe the phrase "patent pending" to any commercial products, methods, or services contemplated by the subject matter claimed. The patent applications reflect Glow's strategy of strengthening its IP portfolio relating to cannabis and nutraceutical ingredient technologies. MyCell® Technology is Glow's proprietary delivery system that optimizes the absorption, bioavailability and effectiveness of natural active compounds including vitamins, cannabinoids and botanicals, using only 100% natural, food-grade components. It transforms poorly absorbed natural compounds into water-compatible concentrates that have fast-acting onset, high-absorption, precision dosing and a clean taste profile. With its portfolio of ingredients, Glow is powering a new era of more efficient, fast-acting, and great tasting functional foods, beverages, supplements, and personal care products.
お知らせ • Dec 09Glow Lifetech Corp., Annual General Meeting, Feb 22, 2023Glow Lifetech Corp., Annual General Meeting, Feb 22, 2023.
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Member of Technical Advisory Board Murray Berall was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Member of Technical Advisory Board Murray Berall was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Sep 17No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
